CYP2C19 and breast carcinoma: Given these contradictory findings, we used a large, publicly available dataset to investigate the association of CYP2C19*2 and CYP2C19*17 variants with breast cancer recurrence in both pre- and postmenopausal women treated with adjuvant tamoxifen therapy for ER-positive breast cancer.